Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) will likely be releasing its Q4 2024 earnings data before the market opens on Friday, February 21st. Analysts expect Protagonist Therapeutics to post earnings of ($0.09) per share and revenue of $56.65 million for the quarter.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, analysts expect Protagonist Therapeutics to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Protagonist Therapeutics Stock Up 0.7 %
Shares of NASDAQ PTGX traded up $0.26 during trading on Friday, reaching $38.75. 659,597 shares of the company traded hands, compared to its average volume of 555,959. The firm has a 50 day simple moving average of $38.41 and a 200-day simple moving average of $41.83. The stock has a market capitalization of $2.31 billion, a PE ratio of 14.57 and a beta of 2.22. Protagonist Therapeutics has a 52-week low of $24.22 and a 52-week high of $48.89.
Insider Buying and Selling at Protagonist Therapeutics
In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the transaction, the chief executive officer now owns 435,208 shares of the company's stock, valued at $20,437,367.68. The trade was a 15.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suneel Gupta sold 103,437 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the transaction, the insider now directly owns 256,174 shares in the company, valued at $11,794,250.96. This represents a 28.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 213,316 shares of company stock valued at $9,816,345 over the last 90 days. 5.40% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on PTGX. The Goldman Sachs Group began coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They set a "neutral" rating and a $47.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 7th. Wedbush reaffirmed an "outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday. StockNews.com downgraded shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. Finally, JMP Securities reissued a "market outperform" rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $56.00.
Check Out Our Latest Analysis on Protagonist Therapeutics
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Recommended Stories
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
